We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Improved Efficacy by Adding Bevacizumab to Chemotherapy in Selected NSCLC Patients.
- Authors
Green, Mark R.
- Abstract
The article reports on the core efficacy of first-line chemotherapy for advanced non-small-cell lung cancer patients in the U.S. A trial conducted by the Eastern Cooperative Oncology Group indicated a direct comparison of standard arboplatin/paclitaxel to the same regimen with the addition of bevacizumab. The study shows significant differences in overall survival, response rate and progression-free survival rate all favoring the addition of bevacizumab. INSET: Key Questions With the Use of Bevacizumab..
- Subjects
UNITED States; DRUG therapy; SMALL cell lung cancer; LUNG cancer; CANCER patients; PACLITAXEL
- Publication
Oncology (08909091), 2005, p4
- ISSN
0890-9091
- Publication type
Article